back to news

Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 Million

Valneva SE, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new ordinary shares, consisting of a private placement of 4,466,880 ordinary shares in Europe (including in France) and other countries outside of the United States (the “European Private Placement”) and a concurrent public offering of 16,560 American Depositary Shares (“ADSs”), each representing two ordinary shares  (the “U.S. Offering”, and, together with the European Private Placement, the “Global Offering”), have exercised in full their option to purchase up to 675,000 additional new ordinary shares in the form of 337,500 ADSs. The additional ADSs will be delivered concurrently with the closing of the Global Offering on or about November 2, 2021.

As a result, the total number of Valneva’s ordinary shares (including in the form of ADSs) issued in the Global Offering amounts to 5,175,000 ordinary shares, including 708,120 ordinary shares represented by 354,060 ADSs, each representing two ordinary shares, bringing the gross proceeds of the Global Offering to approximately $102.0 million (€88.0 million).

Goldman Sachs, acting as the stabilizing agent on its own behalf and on behalf of the other underwriters, reported that no stabilization activities had been carried out and the stabilization period is now closed.

The Company has filed a registration statement, including a prospectus, relating to these securities with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective by the SEC on October 28, 2021. The offering was made by means of a prospectus and copies of the prospectus relating to and describing the terms of the Global Offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: prospectus-ny@ny.email.gs.com or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at +1 877 821 7388 or by email at Prospectus_Department@Jefferies.com.

No prospectus subject to approval by the French Autorité des Marchés Financiers (“AMF”) has been filed in France in connection with the Global Offering.

Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on Euronext Paris.

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.